Kanzo
Online ISSN : 1881-3593
Print ISSN : 0451-4203
ISSN-L : 0451-4203
Search
Advanced search
OR
Browse
Search
Volume 55, Issue 9
Displaying 1-7 of 7 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Original Articles
  • Utility of HBsAg measuring system by BLEIA®-1200, a highly sensitive immunoassay system
    Hiroshi Yatsuhashi, Mika Nakamura, Yuki Kugiyama, Ryu Sasaki, Shigemun ...
    2014 Volume 55 Issue 9 Pages 521-529
    Published: September 19, 2014
    Released on J-STAGE: October 06, 2014
    DOIhttps://doi.org/10.2957/kanzo.55.521
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The utility of BLEIA®-1200, an immunoassay system which performs highly sensitive measurement using bioluminescence and its dedicated reagent BLEIA®' Eiken' HBsAg were reviewed. The detection limit was 0.005 IU/ml which was 6 to 10 times higher in sensitivity than the conventional quantitative reagents. The correlation with chemiluminescent immunoassay (CLIA) was favorable with r=0.983, and parallel shifts were seen in treatment progress. In acute hepatitis B infection, BLEIA® showed positive result as long as HBV-DNA was positive even after CLIA became negative. Although one case in CLIA negative non-B hepatitis patients gave a discrepant result in BLEIA®, it was determined as a case of previous HBV infection since HBcAb was positive. This discrepancy may have been due to the difference in reagent sensitivities. BLEIA® reagent' s utility is suggested in screening for HBV infection, early diagnosis in early phase in HBV infection, early detection in de novo hepatitis infection.
    View full abstract
    Download PDF (1080K)
  • Relationship between proton pump inhibitor therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites
    Shuichi Matsumoto, Naoho Takizawa, Yasunari Kaneyama, Hitoki Miyai, No ...
    2014 Volume 55 Issue 9 Pages 530-536
    Published: September 19, 2014
    Released on J-STAGE: October 06, 2014
    DOIhttps://doi.org/10.2957/kanzo.55.530
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Objective. To demonstrate the relationship between proton pump inhibitor (PPI) and spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites. Material and Method. A total of 157 cirrhotic patients with ascites who underwent diagnostic paracentesis from January 2006 to October 2011 were included. SBP was defined as more than 250/mm3 polymorphonuclear leukocytes with or without a positive culture from the ascitec fluid. Result. 38 patients had SBP and 119 did not. On multivariate analysis, hepatocellular carcinoma (OR=5.09, 95% CI 2.09-13.05; p<0.01), MELD score (>=20, OR=3.57, 95% CI 1.40-9.69, p<0.01), PPI use (OR=2.60, 95% CI 1.13-6.12; p=0.02) were risk factor for SBP. Conclusion. PPI use, as well as with hepatocellular carcinoma and high MELD score, was an independent risk factor for the development of SBP in cirrhotic patients with ascites. We recommend that we should use carefully PPI to cirrhotic patients with ascites. Further prospective studies are warranted to clarify this issue.
    View full abstract
    Download PDF (241K)
Case Reports
  • A case of drug-induced liver injury by celecoxib
    Hideaki Taniguchi, Hiraku Fujita, Kohtaro Shibagaki, Masahiko Kushiro, ...
    2014 Volume 55 Issue 9 Pages 537-543
    Published: September 19, 2014
    Released on J-STAGE: October 06, 2014
    DOIhttps://doi.org/10.2957/kanzo.55.537
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    A 49-year-old woman, who had been followed up for SLE, was admitted to our hospital because of liver dysfunction (AST 1935 IU/l, ALT 1329 IU/l, ALP 553 IU/l). She had received an administration of COX-2 selective inhibitor (celecoxib) for arthralgia 17 days before the admission. After the cessation of celecoxib, her liver function tests improved and reached baseline without additive therapy. We diagnosed celecoxib-induced liver injury, based on criteria proposed in DDW-J 2004 workshop as well as liver biopsy findings obtained on the 14th hospital day. Although celecoxib-induced liver injury is rare, we need to aware the potential of hepatotoxicity.
    View full abstract
    Download PDF (420K)
  • Chronic hepatitis C treated with telaprevir-based triple therapy following interferon combination chemotherapy for non-Hodgkin lymphoma: A case report
    Yoshinori Goto, Michiko Oe, Kazuhiro Miwa, Yutaka Matano
    2014 Volume 55 Issue 9 Pages 544-549
    Published: September 19, 2014
    Released on J-STAGE: October 06, 2014
    DOIhttps://doi.org/10.2957/kanzo.55.544
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Three years ago, a man in his 50s, diagnosed as having chronic hepatitis C, received peginterferon-ribavirin combination therapy, which was unsuccessful. He was re-examined because of weight loss, which revealed generalized lymphadenopathy and splenomegaly. High sIL-2R level and a biopsy of lymph nodes revealed a diagnosis of low grade B-cell lymphoma (follicular lymphoma). Interferon (IFN) α combined with rituximab (R) -alone and R-combined chemotherapies were administered with marked efficacy. After maintenance therapy with R, telaprevir-based triple therapy was administered. Sustained virological response was achieved; there was no reccurence. An association between hepatitis C virus and B-cell lymphoma has been reported, but no policy for the combination of immunochemotherapy with anti-viral therapy has been established. IFN was combined with the initial chemotherapy to suppress liver dysfunction. Triple therapy was performed instead of maintenance therapy. These results suggest that this is an effective treatment considering chronic hepatitis.
    View full abstract
    Download PDF (610K)
Short Communications
  • Tumor marker doubling time can be useful as a prognostic marker for hepatocellular carcinoma
    Nobuyuki Matsumoto, Hiroki Ikeda, Ryuta Shigefuku, Yohei Noguchi, Mori ...
    2014 Volume 55 Issue 9 Pages 550-552
    Published: September 19, 2014
    Released on J-STAGE: October 06, 2014
    DOIhttps://doi.org/10.2957/kanzo.55.550
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We evaluated the clinical utility of doubling times (DT) of alphafeto protein (AFP) and des-gamma-carboxy prothrombin (DCP) as prognostic markers for hepatocellular carcinoma (HCC). Among 151 HCC cases, treated from January 2008 to December 2011, 131 cases (AFP), and 116 cases (DCP) were evaluated. DT-AFP ranged from 10.6 to 4300.9 days (median 169.2 days). DT-DCP ranged from 8.3 to 781.4 days (median: 56.7 days). We decided cutoff DT values as 60 days, based on the median value of DCP. Patients with shorter DT-DCP showed significantly shorter survival time in comparison to residual patients (p=0.016). Our results suggest clinical utility of TM-DT as a prognostic marker of HCC.
    View full abstract
    Download PDF (238K)
  • European-type subgenotype 3e/3sp hepatitis E virus strain identified in a pig as a possible origin of hepatitis E cases in Mie prefecture during 2004-2012
    Hiroshi Okano, Shigehiro Akachi, Tatsunori Nakano, Hiroaki Okamoto
    2014 Volume 55 Issue 9 Pages 553-555
    Published: September 19, 2014
    Released on J-STAGE: October 06, 2014
    DOIhttps://doi.org/10.2957/kanzo.55.553
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The source of European-type subgenotype 3e/3sp hepatitis E virus (HEV) strain that is prevalent in hepatitis E patients in Mie, Japan, remained unknown. The present analyses of stored RNA samples that had been extracted from liver tissues obtained from 85 slaughtered pigs in Mie in 2007, revealed the presence of two HEV strains (swJ-Mie07-37L and swJ-Mie07-80L). The swJ-Mie07-80L strain was classified into subgenotype 3b/3jp, while swJ-Mie07-37L belonged to 3e/3sp and shared high nucleotide sequence identities of 98.3-99.2% with the 3e/3sp strains recovered from hepatitis E patients in Mie during 2004-2012. These results suggest that pigs are important reservoirs for HEV infection even in Mie, although the hepatitis E patients did not recall consuming raw pig liver/intestine before the disease onset.
    View full abstract
    Download PDF (589K)
  • Treatments for advanced hepatocellular carcinoma with major portal vein tumor thrombosis: Sorafenib vs. transcatheter arterial chemo-infusion with cisplatin
    Toshihiko Aibiki, Atsushi Hiraoka, Tomonari Okudaira, Akiko Shiraishi, ...
    2014 Volume 55 Issue 9 Pages 556-558
    Published: September 19, 2014
    Released on J-STAGE: October 06, 2014
    DOIhttps://doi.org/10.2957/kanzo.55.556
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Aim/Background: Though sorafenib has been used against advanced hepatocellular carcinoma with major portal vein tumor thrombosis (HCC-PVTT), the prognosis has not been improved enough. We compared the prognoses of HCC-PVTT after treatment with sorafenib or transcatheter-arterial chemo-infusion with cisplatin (TAI). Method/Patients: Clinical findings for 34 HCC-PVTT patients and without extra-hepatic metastasis, who were treated with sorafenib (n=8) or TAI (n=26), were retrospectively evaluated. Results: Hepatic reserve function was better in the sorafenib-group (Child-Pugh A : B : C ; 8 : 0 : 0 vs. 12 : 10 : 4, P=0.022), whereas the 6-month and 1-year survival rates in the TAI-group were better (52.5%, 31.5% vs. 16.7%, 0%; P=0.004). Conclusion: TAI is thought to be more effective than sorafenib, though establishment of an effective regimen and additional evidence of the efficacy of transcatheter chemo-infusion therapy are needed.
    View full abstract
    Download PDF (247K)
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top